Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;9(10):1109-1118.
doi: 10.1002/ueg2.12156. Epub 2021 Oct 26.

Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy

Alessandra Mangia  1 , Maria Franca Rina  2 , Antonio Canosa  3 , Valeria Piazzolla  1 , Maria Maddalena Squillante  1 , Ernesto Agostinacchio  4 , Giovanna Cocomazzi  1 , Egidio Visaggi  5 , Nazario Augello  6 , Camilla Iannuzziello  2 , Mattia Falcone  7 , Angelo De Giorgi  8 , Fausto Campanozzi  9
Affiliations

Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy

Alessandra Mangia et al. United European Gastroenterol J. 2021 Dec.

Abstract

Background: Rates of Hepatitis C virus (HCV) testing and diagnosis are variable among people who use drugs (PWUD). In Puglia in 2018, of 871 subjects screened, 38% had HCV antibodies (HCVAb). Despite sustained virologic response at week 12 Sustained virologic response (SVR12) rates >95%, addiction centers in Italy are not allowed to prescribe direct-acting antivirals (DAA).

Aim: To increase testing and linkage to care a dedicated program including "ad hoc" transportation and fast-track access to care was offered to PWUD from Puglia.

Methods: Over 12 months, 1,470 individuals seen at 15 Services for Dependence (SERDs) underwent screening. For HCVAb positive, a fast-track evaluation was offered at our Hepatology Unit. Patients were subsequently taken to their pharmacists to receive the prescribed DAA regimen. Treatment and adherence were supervised by SERDs physicians, SVR12 assessed at our unit. The scalability of the process was based on both, number of patients screened in our region in 2018, and number of PWUD diagnosed and treated at our center during 2018-2019.

Results: Of 1,470 individuals screened, 634 (43.1%) tested HCVAb positive. Overall, 231 were RNA positive, 54% of whom on opioid agonist therapy (OAT) and 32% with cirrhosis. Median interval between RNA assessment and treatment start was 22 days (0-300). Patients received 12-week sofosbuvir/velpatasvir regimen without Ribavirin; in 220 patients who completed treatment, SVR12 was 98.6%. Among GT3, SVR12 was 98%. No re-infection was observed. Improvements in screening, and linkage to care were registered.

Conclusions: A PWUD-tailored service led to HCV care cascade improvement and high SVR12 rates. Despite history of drug addiction, social instability and logistic barriers, micro-elimination programs providing dedicated care are key drivers of success.

Trial registration: ClinicalTrials.gov NCT03923595.

Keywords: HCV; PWUD; antiviral treatment; cirrhosis; hepatitis C; linkage to care; micro-elimination; people who use drugs; screening; sofosbuvir/velpatasvir.

PubMed Disclaimer

Conflict of interest statement

Maria Franca Rina, Antonio Canosa, Valeria Piazzolla, Maria Maddalena Squillante, Ernesto Agostinacchio, Giovanna Cocomazzi, Egidio Visaggi, Nazario Augello, Camilla Iannuzziello, Mattia Falcone, Angelo De Giorgi, Fausto Campanozzi: None. Alessandra Mangia disclose fees for consulting, speakers bureaus and research support from BMS, Gilead, MSD, Intercept.

Figures

FIGURE 1
FIGURE 1
Proportion of patients HCVAb positive of 1470 PWD screened. Abbreviation: HCVAb, HCV antibodies
FIGURE 2
FIGURE 2
HCV care cascade: total number of subjects per group and rate of positive among the previous group. Abbreviation: HCV, Hepatitis C virus
FIGURE 3
FIGURE 3
SVR12 by LS results suggesting presence of cirrhosis/bridging fibrosis in 220 PWUD who completed treatment. Abbreviations: LS, liver stiffness; PWUD, people who use drugs; SVR12, sustained virologic response at week 12
FIGURE 4
FIGURE 4
SVR12 by genotype in 220 PWUD who completed treatment. Abbreviations: PWUD, people who use drugs; SVR12, sustained virologic response at week 12
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Global health sector strategy on viral hepatitis 2016–21. https://www.who.int/hepatitis/strategy2016‐2021/ghss‐hep/en/. Accessed January 2021.
    1. Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high‐income countries. Liver Int. 2020. Mar;40(3):522–9. 10.1111/liv.14324. PMID: 31815353. - DOI - PubMed
    1. Wingrove C, Ferrier L, James C, Wang S. The impact of COVID‐19 on hepatitis elimination. Lancet Gastroenterol Hepatol. 2020. Sep;5 (9):792–4. 10.1016/S2468-1253(20)30238-7. PMID: 32730783 PMCID: PMC7384773. - DOI - PMC - PubMed
    1. AASLD . Call to action for liver associations to advance progress towards viral hepatitis elimination: a focus on simplified approaches to HCV testing and cure. AASLD; 2019.
    1. Lazarus JV, Wiktor SZ, Colombo M, Thursz M. Microelimination a path to global elimination of hepatitis C. J Hepatol. 2017. Oct;67(4):665–6. 10.1016/j.jhep.2017.06.033. PMID: 28760329. - DOI - PubMed

Publication types

Associated data